Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Chang TC, Liao SL

Journal of endocrinological investigation1 May 2006Cited by 31 (Europe PMC)

PMID16794364DOI10.1007/bf03344124PepBankPUB-16794364

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In active Graves' ophthalmopathy, lanreotide did not significantly decrease Clinical Activity Score versus placebo at 12 weeks.
In plain wordsIn active Graves' eye disease, lanreotide did not significantly improve Clinical Activity Score versus placebo.
Peptide
Lanreotide
Outcome
No significant changeClinical Activity Score
Study
n = 60
Comparator
placebo
Analysis
Primary
Outcome group
Eye function · Eye
Studied dose
30 mg every two weeks · intramuscular · 12 weeksAs given in this study (human).
Source sentences
Summary
At the end of the 12 weeks, the mean CAS was not significantly decreased in the lanreotide group compared to the placebo group.
3 context sentences(design, population, supporting numbers)
Summary · context
The Clinical Activity Score (CAS) was the primary efficacy criterion.
Summary · context
The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO.
Summary · context
Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks.
Report a problemFND-1679436401
02HumanRandomized controlled trialEfficacy outcome
In active Graves' ophthalmopathy, proptosis did not differ significantly between lanreotide and placebo at 12 weeks.
In plain wordsIn active Graves' eye disease, eye protrusion did not differ significantly between lanreotide and placebo.
Peptide
Lanreotide
Outcome
No significant changeProptosis
Study
n = 60
Comparator
placebo
Outcome group
Eye function · Eye
Studied dose
30 mg every two weeks · intramuscular · 12 weeksAs given in this study (human).
Source sentences
Summary
The overall mean difference of proptosis between these two groups also did not reach significance at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO.
Summary · context
Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks.
Report a problemFND-1679436402
03HumanRandomized controlled trialEfficacy outcome
In active Graves' ophthalmopathy, lanreotide improved downward-gaze diplopia versus placebo (p = 0.03).
In plain wordsIn active Graves' eye disease, lanreotide improved downward-gaze double vision versus placebo.
Peptide
Lanreotide
Outcome
Direction not reportedDownward-gaze diplopia
Study
n = 60
Comparator
placebo
Outcome group
Eye function · Eye
Studied dose
30 mg every two weeks · intramuscular · 12 weeksAs given in this study (human).
Measurements
P value
0.03
lanreotide versus placebo, diplopia at downward gaze
Source sentences
Summary
Only diplopia at downward gaze had significant improvement for the lanreotide- treated group vs placebo group (p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO.
Summary · context
Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks.
Report a problemFND-1679436403
04HumanRandomized controlled trialEfficacy outcome
In active Graves' ophthalmopathy, other measured eye outcomes did not differ between lanreotide and placebo.
In plain wordsIn active Graves' eye disease, other measured eye outcomes did not differ between lanreotide and placebo.
Peptide
Lanreotide
Outcome
No significant changeOther eye outcome measures
Study
n = 60
Comparator
placebo
Outcome group
Eye function · Eye
Studied dose
30 mg every two weeks · intramuscular · 12 weeksAs given in this study (human).
Source sentences
Summary
No differences were observed between the two groups compared to other outcome measures.
3 context sentences(design, population, supporting numbers)
Summary · context
Proptosis, diplopia, corneal erosion or ulcer, visual acuity, extraocular muscle movement and intraocular pressure were also evaluated.
Summary · context
The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO.
Summary · context
Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks.
Report a problemFND-1679436404
05HumanRandomized controlled trialEfficacy outcome
In Graves' ophthalmopathy, 10 lanreotide patients versus 14 placebo patients received eye surgery during 24-month follow-up (p = 0.29).
In plain wordsIn Graves' eye disease, eye surgery during follow-up did not differ significantly between lanreotide and placebo.
Peptide
Lanreotide
Outcome
No significant changeEye surgery during follow-up
Study
n = 60
Comparator
placebo
Outcome group
Eye function · Eye
Studied dose
30 mg every two weeks · intramuscular · 12 weeksAs given in this study (human).
Measurements
patients receiving eye surgery
10 patients
lanreotide group, 24-month follow-up
patients receiving eye surgery
14 patients
placebo group, 24-month follow-up
Source sentences
Summary
During the 24-month follow-up after the clinical trial, 14 patients received eye surgery in the placebo group compared with 10 patients in the lanreotide group (p = 0.29).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO.
Summary · context
Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks.
Report a problemFND-1679436405
06HumanRandomized controlled trialEfficacy outcome
In Graves' ophthalmopathy, two lanreotide patients versus six placebo patients received methylprednisolone pulse therapy (p = 0.25).
In plain wordsIn Graves' eye disease, methylprednisolone pulse therapy did not differ significantly between lanreotide and placebo.
Peptide
Lanreotide
Outcome
No significant changeMethylprednisolone pulse therapy
Study
n = 60
Comparator
placebo
Outcome group
Eye function · Eye
Studied dose
30 mg every two weeks · intramuscular · 12 weeksAs given in this study (human).
Measurements
patients receiving methylprednisolone pulse therapy
2 patients
lanreotide group, 24-month follow-up
patients receiving methylprednisolone pulse therapy
6 patients
placebo group, 24-month follow-up
Source sentences
Summary
Six patients received methylprednisolone pulse therapy in the placebo group and two patients in the lanreotide group (p = 0.25).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO.
Summary · context
Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks.
Report a problemFND-1679436406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.